Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 5/2008

01-05-2008 | Original Research Article

Use of Statins and the Risk of Parkinson’s Disease

A Retrospective Case-Control Study in the UK

Authors: Claudia Becker, Susan S. Jick, Dr Christoph R. Meier

Published in: Drug Safety | Issue 5/2008

Login to get access

Abstract

Background: Case reports have related the use of HMG-CoA reductase inhibitors (‘statins’) to Parkinson’s disease (PD). Paradoxically, however, statins may have potentially beneficial effects on neurodegenerative diseases due to their anti-inflammatory properties.
Objective: To explore the risk of the development of PD in association with untreated hyperlipidaemia and with hyperlipidaemia treated with lipid-lowering drugs in the UK primary care setting.
Methods: We conducted a case-control analysis using the UK-based General Practice Research Database (GPRD). Cases were incident PD cases ≥40 years of age between 1994 and 2005. One control was matched to each PD case based on age, sex, general practice and index date. Lipid-lowering drug use was assessed by exposure timing (current vs past use) and by exposure duration (1–9,10–29 or≥30 prescriptions) prior to the index date for both cases and controls. Odds ratios (OR) were calculated using conditional logistic regression, adjusted for body mass index, smoking and various cardiovascular, metabolic and psychiatric co-morbidities.
Results: We identified 3637 cases with an incident idiopathic PD diagnosis, and the same number of controls. Compared with patients without hyperlipidaemia, those with untreated hyperlipidaemia did not have an altered relative PD risk (adjusted OR 0.98, 95% CI 0.74, 1.30). The adjusted ORs for current use of ≥30 prescriptions for statins or fibrates compared with non-use of statins or fibrates were 1.06 (95% CI 0.75, 1.51) and 1.25 (95% CI 0.51, 3.06), respectively.
Conclusions: In this observational study, the long-term use of statins or fibrates was not associated with a substantially altered relative risk of developing PD.
Literature
1.
2.
Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003; 53 Suppl. 3: S26–36; discussion S36-8PubMedCrossRef
3.
Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson’s disease. Parkinsonism Relat Disord 2005; 11 Suppl. 1: S9–15PubMedCrossRef
4.
Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol 1998; 44: S89–98PubMed
5.
Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005; 1037: 1–6PubMedCrossRef
6.
7.
Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia [erratum appears in Lancet 2001 Feb 17; 357 (9255): 562]. Lancet 2000; 356: 1627–31PubMedCrossRef
8.
Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005; 57: 561–9PubMed
9.
Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62: 1047–51PubMedCrossRef
10.
Levesque LE, Delaney JA, Etminan M, et al. Pharmacologic interventions for the prevention of Alzheimer’s disease: an example of reverse protopathic bias [abstract no. 65]. 22nd International conference on pharmacoepidemiology and therapeutic risk management; 2006 Aug 24–27; Lisbon. Pharmacoepidemiol Drug Saf 2006; 15: S31CrossRef
11.
Muller T, Kuhn W, Pohlau D, et al. Parkinsonism unmasked by lovastatin. Ann Neurol 1995; 37: 685–6PubMedCrossRef
12.
Muller T. Statininduziertes Parkinson-Syndrom. Leserbrief zum Beitrag von J. Finsterer in “Der Nervenarzt” (2003) 74: 115–122. Nervenarzt 2003; 74: 726–7PubMedCrossRef
13.
Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord 2007; 22: 377–81PubMedCrossRef
14.
de Lau LM, Koudstaal PJ, Hofman A, et al. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol 2006; 164: 998–1002PubMedCrossRef
15.
16.
Lawson DH, Sherman V, Hollowell J. The General Practice Research Database: scientific and ethical advisory group. QJM 1998; 91: 445–52PubMedCrossRef
17.
Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27: 871–81PubMedCrossRef
18.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686–9PubMedCrossRef
19.
20.
Hernan MA, Logroscino G, Rodriguez LA. A prospective study of alcoholism and the risk of Parkinson’s disease. J Neurol 2004; 251 Suppl. 7: vII14–7PubMedCrossRef
21.
Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66: 1097–9PubMedCrossRef
22.
Lieberman A, Lyons K, Levine J, et al. Statins, cholesterol, coenzyme Q10, and Parkinson’s disease. Parkinsonism Relat Disord 2005; 11: 81–4PubMedCrossRef
23.
Rajanikant GK, Zemke D, Kassab M, et al. The therapeutic potential of statins in neurological disorders. Curr Med Chem 2007; 14: 103–12PubMedCrossRef
24.
Wang Q, Wang PH, McLachlan C, et al. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005; 1045: 229–33PubMedCrossRef
25.
Wang Q, Tang XN, Wang L, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 2006; 408: 189–93PubMedCrossRef
26.
27.
Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007; 30: 195–201PubMedCrossRef
28.
29.
Sinzinger H, Mayr F, Schmid P, et al. Sleep disturbance and appetite loss after lovastatin [letter]. Lancet 1994; 343: 973PubMedCrossRef
30.
Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195–204PubMedCrossRef
31.
Shults CW, Haas RH, Passov D, et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997; 42: 261–4PubMedCrossRef
32.
Schapira AH, Mann VM, Cooper JM, et al. Mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol 1992; 32 Suppl.: S116–24PubMedCrossRef
33.
Kaikkonen J, Nyyssonen K, Tuomainen TP, et al. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999; 443: 163–6PubMedCrossRef
34.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931–4PubMedCrossRef
35.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226–9PubMed
36.
Laaksonen R, Ojala JP, Tikkanen MJ, et al. Serum ubiquinone concentrations after short-and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46: 313–7PubMedCrossRef
37.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 Suppl.: S137–44PubMedCrossRef
38.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541–50PubMedCrossRef
39.
Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett 2003; 341: 201–4PubMedCrossRef
40.
Kreisler A, Gele P, Wiart JF, et al. Lipid-lowering drugs in the MPTP mouse model of Parkinson’s disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007; 1135: 77–84PubMedCrossRef
41.
Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 2005; 65: 1575–83PubMedCrossRef
42.
43.
Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol 1968; 88: 149–58PubMed
44.
45.
Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007; 64: 576–80PubMedCrossRef
Metadata
Title
Use of Statins and the Risk of Parkinson’s Disease
A Retrospective Case-Control Study in the UK
Authors
Claudia Becker
Susan S. Jick
Dr Christoph R. Meier
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 5/2008
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200831050-00004

Other articles of this Issue 5/2008

Drug Safety 5/2008 Go to the issue

Conference Paper

European Legislation on Herbal Medicines

Correspondence

TNF-α Inhibitors and Leukaemia: International Pharmacovigilance Reports

Conference Paper

Assessment of the Risk of Fragrance Allergy in the General Population

Conference Paper

The European Herbal Medicines Directive

Original Research Article

Improving Global Monitoring of Vaccine Safety

Conference Paper

Phytotherapic Compounds